

John C Stevenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5220471/publications.pdf>

Version: 2024-02-01

118
papers

6,378
citations

71102

41
h-index

66911

78
g-index

119
all docs

119
docs citations

119
times ranked

5295
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex- and menopause-associated changes in body-fat distribution. <i>American Journal of Clinical Nutrition</i> , 1992, 55, 950-954.	4.7	641
2	Influence of age and menopause on serum lipids and lipoproteins in healthy women. <i>Atherosclerosis</i> , 1993, 98, 83-90.	0.8	482
3	Determinants of bone density in normal women: risk factors for future osteoporosis?. <i>BMJ: British Medical Journal</i> , 1989, 298, 924-928.	2.3	369
4	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Maturitas</i> , 2014, 79, 122-132.	2.4	213
5	Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 846-853.	3.4	212
6	Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. <i>Endocrine Reviews</i> , 2017, 38, 173-188.	20.1	206
7	Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 166, 950-955.	1.3	200
8	Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. <i>Lancet, The</i> , 1995, 346, 89-90.	13.7	200
9	The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. <i>European Journal of Clinical Investigation</i> , 1993, 23, 466-473.	3.4	180
10	Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. <i>Climacteric</i> , 2011, 14, 302-320.	2.4	176
11	17 β -Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1998, 1406, 169-174.	3.8	149
12	Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. <i>European Heart Journal</i> , 2021, 42, 967-984.	2.2	136
13	Is there a menopausal metabolic syndrome?. <i>Gynecological Endocrinology</i> , 1997, 11, 341-355.	1.7	122
14	Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2019, 180, 41-50.	3.7	109
15	Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. <i>Atherosclerosis</i> , 2016, 254, 282-290.	0.8	105
16	Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. <i>Calcified Tissue International</i> , 1996, 59, 6-11.	3.1	102
17	Insulin resistance: syndrome or tendency?. <i>Lancet, The</i> , 1995, 346, 100-103.	13.7	101
18	Hormone replacement therapy with dydrogesterone and 17beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1997, 104, 298-304.	2.3	95

#	ARTICLE	IF	CITATIONS
19	Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. <i>Maturitas</i> , 2017, 101, 23-30.	2.4	94
20	Menopause and diabetes: EMAS clinical guide. <i>Maturitas</i> , 2018, 117, 6-10.	2.4	91
21	Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. <i>Maturitas</i> , 2018, 107, 7-12.	2.4	88
22	Effects of oral and transdermal 17 β -estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 742-747.	3.4	81
23	EMAS position statement: Predictors of premature and early natural menopause. <i>Maturitas</i> , 2019, 123, 82-88.	2.4	80
24	The Prevention of Osteoporosis Using Sequential Low-Dose Hormone Replacement Therapy with Estradiol-17 β and Dydrogesterone. <i>Osteoporosis International</i> , 2001, 12, 251-258.	3.1	79
25	A woman's journey through the reproductive, transitional and postmenopausal periods of life: Impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. <i>Maturitas</i> , 2011, 70, 197-205.	2.4	71
26	The glycolytic pathway to coronary heart disease: A hypothesis. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 657-662.	3.4	68
27	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). <i>Maturitas</i> , 2016, 89, 63-72.	2.4	67
28	Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. <i>Clinical Science</i> , 1992, 83, 489-494.	4.3	66
29	Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. <i>European Journal of Endocrinology</i> , 1993, 128, 259-262.	3.7	66
30	Coronary heart disease and menopause management: The swinging pendulum of HRT. <i>Atherosclerosis</i> , 2009, 207, 336-340.	0.8	63
31	Cardiovascular risk assessment in women – an update. <i>Climacteric</i> , 2016, 19, 329-336.	2.4	62
32	Premature Ovarian Insufficiency and Long-Term Health Consequences. <i>Current Vascular Pharmacology</i> , 2019, 17, 604-609.	1.7	61
33	Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. <i>British Journal of Haematology</i> , 2004, 124, 802-808.	2.5	54
34	The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. <i>Maturitas</i> , 2017, 99, 27-36.	2.4	54
35	EMAS position statement: Testosterone replacement therapy in the aging male. <i>Maturitas</i> , 2016, 84, 94-99.	2.4	53
36	The menopausal hot flush: a review. <i>Climacteric</i> , 2017, 20, 296-305.	2.4	52

#	ARTICLE	IF	CITATIONS
37	Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. <i>Clinical Endocrinology</i> , 2004, 60, 541-549.	2.4	48
38	Justification for the use of HRT in the long-term prevention of osteoporosis. <i>Maturitas</i> , 2005, 51, 113-126.	2.4	47
39	The WHI: the effect of hormone replacement therapy on fracture prevention. <i>Climacteric</i> , 2012, 15, 263-266.	2.4	47
40	Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. <i>Obstetrics and Gynecology</i> , 1994, 84, 222-6.	2.4	47
41	Type and route of estrogen administration. <i>Climacteric</i> , 2009, 12, 86-90.	2.4	43
42	Osteoporosis management in patients with breast cancer: EMAS position statement. <i>Maturitas</i> , 2017, 95, 65-71.	2.4	42
43	Oral ultra-low dose continuous combined hormone replacement therapy with 0.5mg 17 β -oestradiol and 2.5mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study. <i>Maturitas</i> , 2010, 67, 227-232.	2.4	41
44	17 beta-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. <i>European Journal of Endocrinology</i> , 1997, 137, 205-208.	3.7	40
45	Cardiovascular effects of oestrogens. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 74, 387-393.	2.5	40
46	EMAS recommendations for conditions in the workplace for menopausal women. <i>Maturitas</i> , 2016, 85, 79-81.	2.4	40
47	Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysis. <i>Maturitas</i> , 2020, 135, 74-79.	2.4	40
48	Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. <i>European Heart Journal</i> , 2006, 27, 2046-2053.	2.2	35
49	HRT and cardiovascular disease. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2009, 23, 109-120.	2.8	35
50	Cardiovascular Risk in Perimenopausal Women. <i>Current Vascular Pharmacology</i> , 2019, 17, 591-594.	1.7	35
51	Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 1. The Collaborative Reanalysis. <i>Journal of Family Planning and Reproductive Health Care</i> , 2011, 37, 103-109.	0.8	34
52	Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Table 1. <i>Journal of Family Planning and Reproductive Health Care</i> , 2012, 38, 102-109.	0.8	33
53	Hormone therapy for first-line management of menopausal symptoms: Practical recommendations. <i>Women's Health</i> , 2019, 15, 174550651986400.	1.5	33
54	HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?. <i>Human Reproduction</i> , 2006, 21, 1668-1671.	0.9	29

#	ARTICLE	IF	CITATIONS
55	Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. <i>Maturitas</i> , 2013, 76, 10-21.	2.4	29
56	Primary prevention of coronary heart disease in women. <i>Menopause International</i> , 2008, 14, 40-45.	1.6	28
57	Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. <i>Clinical Endocrinology</i> , 2003, 58, 30-35.	2.4	26
58	Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. <i>Osteoporosis International</i> , 1995, 5, 344-348.	3.1	25
59	17 β -Estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. <i>Maturitas</i> , 2001, 38, 197-203.	2.4	25
60	The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits – an attempt to interpret the Women's Health Initiative results. <i>Gynecological Endocrinology</i> , 2006, 22, 303-317.	1.7	25
61	HRT and the primary prevention of cardiovascular disease. <i>Maturitas</i> , 2007, 57, 31-34.	2.4	23
62	A model of care for healthy menopause and ageing: EMAS position statement. <i>Maturitas</i> , 2016, 92, 1-6.	2.4	23
63	Menopause-associated risk of cardiovascular disease. <i>Endocrine Connections</i> , 2022, 11, .	1.9	23
64	Current management of pelvic organ prolapse in aging women: EMAS clinical guide. <i>Maturitas</i> , 2018, 110, 118-123.	2.4	21
65	Cardiometabolic health in premature ovarian insufficiency. <i>Climacteric</i> , 2021, 24, 474-480.	2.4	21
66	Hormone replacement therapy: Review, update, and remaining questions after the women's health initiative study. <i>Current Osteoporosis Reports</i> , 2004, 2, 12-16.	3.6	20
67	Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women. <i>Maturitas</i> , 2002, 42, 233-242.	2.4	19
68	Hormone replacement therapy and cardiovascular disease revisited. <i>Menopause International</i> , 2009, 15, 55-57.	1.6	18
69	Risks and benefits of hormone therapy: has medical dogma now been overturned?. <i>Climacteric</i> , 2014, 17, 215-222.	2.4	18
70	1 and 2 mg 17 β -estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. <i>Climacteric</i> , 2005, 8, 352-359.	2.4	17
71	The metabolic and cardiovascular consequences of HRT. <i>The British Journal of Clinical Practice</i> , 1995, 49, 87-90.	0.2	17
72	Effects of equine oestrogens on markers of vasoactive function in human coronary artery endothelial cells. <i>Molecular and Cellular Endocrinology</i> , 1999, 150, 33-37.	3.2	16

#	ARTICLE	IF	CITATIONS
73	Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement. <i>Maturitas</i> , 2017, 100, 86-91.	2.4	16
74	HRT and breast cancer risk: a realistic perspective. <i>Climacteric</i> , 2011, 14, 633-636.	2.4	15
75	HRT and breast cancer: a million women ride again. <i>Climacteric</i> , 2020, 23, 226-228.	2.4	15
76	7 Metabolic effects of the menopause and oestrogen replacement. <i>Bailliere's Clinical Obstetrics and Gynaecology</i> , 1996, 10, 449-467.	0.6	14
77	Long-term effects of hormone replacement therapy. <i>Lancet, The</i> , 2003, 361, 253-254.	13.7	14
78	The Metabolic Basis for the Effects of HRT on Coronary Heart Disease. <i>Endocrine</i> , 2004, 24, 239-244.	2.2	13
79	Primary Prevention of Cardiovascular Disease with HRT. <i>Women's Health</i> , 2012, 8, 63-74.	1.5	13
80	Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference. <i>Drugs in Context</i> , 2020, 9, 1-12.	2.2	12
81	Non-invasive assessment of vascular function. Paradoxical vascular response to intravenous glucose in coronary heart disease. <i>European Heart Journal</i> , 2000, 21, 39-44.	2.2	10
82	Where has WHI led us now?. <i>Maturitas</i> , 2004, 48, 1-2.	2.4	10
83	Prevention of osteoporosis: one step forward, two steps back. <i>Menopause International</i> , 2011, 17, 137-141.	1.6	10
84	Recommendations on the management of fragility fracture risk in women younger than 70 years. <i>Gynecological Endocrinology</i> , 2012, 28, 770-786.	1.7	10
85	Thiazide diuretics, β -blockers, and coronary heart disease. <i>Lancet, The</i> , 1990, 335, 1534-1535.	13.7	9
86	Misrepresentation of the risk of ovarian cancer among women using menopausal hormones. Spurious findings in a meta-analysis. <i>Maturitas</i> , 2015, 81, 323-326.	2.4	8
87	Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β -estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms. <i>Maturitas</i> , 2020, 139, 20-26.	2.4	8
88	Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, high-density lipoprotein subfractions and apolipoproteins in postmenopausal women in a two-year, randomized, double-blind, placebo-controlled trial. <i>Clinical Endocrinology</i> , 2020, 92, 303-311.	2.4	7
89	Effects of tibolone or continuous combined oestradiol/norethisterone acetate on glucose and insulin metabolism. <i>Clinical Endocrinology</i> , 2013, 78, 297-302.	2.4	6
90	The impact of bone loss in women with endometriosis. <i>International Journal of Gynecology and Obstetrics</i> , 1995, 50, S11-S15.	2.3	5

#	ARTICLE	IF	CITATIONS
91	Metabolic effects of hormone replacement therapy. The Journal of the British Menopause Society, 2004, 10, 157-161.	1.3	5
92	Bisphosphonates and Atypical Femoral Shaft Fractures. New England Journal of Medicine, 2011, 365, 377-377.	27.0	5
93	A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity. The Journal of the British Menopause Society, 2006, 12, 8-10.	1.3	4
94	Coronary heart disease in women. New England Journal of Medicine, 2000, 343, 1891; author reply 1892-3.	27.0	3
95	Helping women make the right HRT choice. Practice Nursing, 2005, 16, 73-78.	0.1	2
96	Does estrogen therapy reduce coronary artery calcification in postmenopausal women?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 654-655.	3.3	2
97	Cardiovascular disease in women. Menopause International, 2008, 14, 5-5.	1.6	2
98	Long-term benefits and risks of HRT (Section 11): Cardiovascular disease. Post Reproductive Health, 2016, 22, 80-82.	0.9	2
99	The Influence of Sex Steroids on Affairs of the Heart. ISGE Series, 2014, , 225-231.	0.2	2
100	Hormone replacement therapy and cardiovascular disease. The Obstetrician and Gynaecologist, 2005, 7, 1-4.	0.4	1
101	Conflicts of interest, smoke and mirrors. Climacteric, 2015, 18, 348-349.	2.4	1
102	BMS consensus statement for primary prevention of coronary heart disease in women. Post Reproductive Health, 2019, 25, 64-69.	0.9	1
103	Interventions for Osteoporosis. , 2007, , 351-375.		1
104	Are changes in lipoproteins during HRT important?. British Journal of Obstetrics and Gynaecology, 1996, 103 Suppl 13, 39-43; discussion 43-4.	0.9	1
105	FemostonÂ®, menopause and the cardiovascular system. Gynecological Endocrinology, 1996, 10, 118-118.	1.7	0
106	Late prevention of hip fractures with hormone replacement therapy. Osteoporosis International, 1996, 6, 64-67.	3.1	0
107	Breast cancer and HRT: general practice must not pick up the wrong pieces. Maturitas, 2003, 46, 109-110.	2.4	0
108	Metabolic consequences of the menopause. Menopause International, 2007, 13, 196-197.	1.6	0

#	ARTICLE	IF	CITATIONS
109	An Atlas of Osteoporosis. , 2007, , .		0
110	Long-term benefits and risks of HRT (Section 11): Osteoporosis. Post Reproductive Health, 2016, 22, 92-94.	0.9	0
111	The Effect of Menopause and HRT on Coronary Heart Disease. ISGE Series, 2018, , 187-193.	0.2	0
112	The True Risks of HRT. ISGE Series, 2018, , 245-252.	0.2	0
113	Prevention and treatment of osteoporosis in women. Post Reproductive Health, 2018, 24, 167-170.	0.9	0
114	Premature Ovarian Insufficiency: Practical Management Approaches. ISGE Series, 2019, , 143-153.	0.2	0
115	David McKay Hart MD, FRCS (Glasgow), FRCOG (1936â€“2020). Post Reproductive Health, 2021, 27, 126-127.	0.9	0
116	David McKay Hart, MD, FRCS (Glasgow), FRCOG. Climacteric, 2021, 24, 421-421.	2.4	0
117	Is It Safe to Prevent and Treat Postmenopausal Osteoporosis?. ISGE Series, 2014, , 207-214.	0.2	0
118	Effects of weight changes on the bone. Climacteric, 2012, 15, 98-9.	2.4	0